Sign in to view content

Canadian Treat-and-Extend Trial With Ranibizumab in nAMD Patients: CANTREAT 36-Month Extension Results

Peter J. Kertes, MD, FRCS(C)

Video
Published 2020

Related

Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Should Baseline Characteristics Affect Choice of Treatment?
Susan B. Bressler, MD, FASRS
Annual Meeting Talks
2018
LADDER Trial of the Port Delivery System with Ranibizumab: Initial Study Results
Carl C. Awh, MD, FASRS
Annual Meeting Talks
2018
Fluorescein Angiographic Evaluation of Peripheral Retinal Vasculature After Ranubizumab Injection for Type I Retinopathy of Prematurity
Clio Armitage Harper, MD
Annual Meeting Talks
2016

Category: AMD-Neovascular

See more